REFERENCES
1. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT jnsignalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 2015;113:365-71.
2. O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in Immunity, Immunodeficiency, and Cancer. N Engl J Med 2013;368:161-70.
3. O’Sullivan JM, Harrison CN. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplas ms. Mol Cell Endocrinol 2017;451:71-9.
4. Khanna P, Lee JS, Sereemaspun A, Lee H, Baeg GH. GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling. Sci Rep 2018;8:9511.
5. Haque I, Ghosh A, Acup S, Banerjee S, Dhar K, et al. Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. BMC Cancer 2018;18:99.
6. Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers (Basel) 2019;11:1704.
7. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. Constitutive activation of stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000;97:4227-32.
8. Wu CS, Wei KL, Chou JL, Lu CK, Hsieh CC, et al. Aberrant JAK/STAT signaling suppresses TFF1 and TFF2 through epigenetic silencing of GATA6 in gastric cancer. Int J Mol Sci 2016;17:1467.
9. Shang AQ, Wu J, Bi F, Zhang YJ, Xu LR, et al. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. Cancer Biol Ther 2017;18:314-22.
10. Nishi M, Batsaikhan BE, Yoshikawa K, Higashijima J, Tokunaga T, et al. High STAT4 expression indicates better disease-free survival in patients with gastric cancer. Anticancer Res 2017;37:6723-9.
11. Nikitakis N, Siavash H, Sauk J. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr Cancer Drug Targets 2005;4:637-51.
12. Khanna P, Chua PJ, Bay BH, Baeg GH. The JAK/STAT signaling cascade in gastric carcinoma (Review). Int J Oncol 2015;47:1617-26.
13. Tabassum S, Abbasi R, Ahmad N, Farooqi AA. Targeting of JAK-STAT signaling in breast cancer: therapeutic strategies to overcome drug resistance. Adv Exp Med Biol 2019;1152:271-81.
14. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32:2601-13.
15. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
16. Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs 2015;75:297-308.
17. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
18. Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016;30:1701-7.
19. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372:426-35.
20. Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol 2017;96:1113-20.
21. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120:513-20.
22. Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016;101:821-9.
23. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci 2018;27:1984-2009.
24. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-3.
27. Alvarez JV, Frank DA, Alvarez J, Lab F. Genome-wide analysis of STAT target genes: Elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 2004;3:1045-50.
28. Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett 2018;415:117-28.
29. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol 2001;70:348-56.
30. Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A. Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci 2017;108:574-80.
31. Niu GJ, Xu JD, Yuan WJ, Sun JJ, Yang MC, et al. Protein inhibitor of activated STAT (PIAS) negatively regulates the JAK/STAT pathway by inhibiting STAT phosphorylation and translocation. Front Immunol 2018;9:2392.
32. Frankson R, Yu ZH, Bai Y, Li Q, Zhang RY, et al. Therapeutic targeting of oncogenic tyrosine phosphatases. Cancer Res 2017;77:5701-5.
33. Kim M, Morales LD, Jang IS, Cho YY, Kim DJ. Protein tyrosine phosphatases as potential regulators of STAT3 signaling. Int J Mol Sci 2018;19:2708.
34. Chen YW, Guo T, Shen L, Wong KY, Tao Q, et al. Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. Blood 2015;125:1589-600.
35. Lee M, Hirpara JL, Eu JQ, Sethi G, Wang L, et al. Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors. Redox Biol 2019;25:101073.
36. Zhang X, Guo A, Yu J, Possemato A, Chen Y, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A 2007;104:4060-4.
37. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 2009;106:9435-40.
38. Shahmarvand N, Nagy A, Shahryari J, Ohgami RS. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci 2018;109:926-33.
39. Shi M, He R, Feldman AL, Viswanatha DS, Jevremovic D, et al. STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. Hum Pathol 2018;73:74-81.
40. Yang S, Luo C, Gu Q, Xu Q, Wang G, et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget 2016;7:5461-9.
41. Kan Z, Zheng H, Liu X, Li S, Barber TD, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013;23:1422-33.
42. Igelmann S, Neubauer HA, Ferbeyre G. STAT3 and STAT5 activation in solid cancers. Cancers (Basel) 2019;11:1428.
43. Orlova A, Wagner C, De Araujo ED, Bajusz D, Neubauer HA, et al. Direct targeting options for STAT3 and STAT5 in cancer. Cancers (Basel) 2019;11:1930.
44. Wang Y, Wu C, Zhang C, Li Z, Zhu T, et al. TGF-β-induced STAT3 overexpression promotes human head and neck squamous cell carcinoma invasion and metastasis through malat1/miR-30a interactions. Cancer Lett 2018;436:52-62.
45. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002;13:355-62.
46. Bu LL, Yu GT, Wu L, Mao L, Deng WW, et al. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. J Dent Res 2017;96:1027-34.
47. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004;23:4921-9.
48. Wu X, Tao P, Zhou Q, Li J, Yu Z, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 2017;8:20741-50.
49. Pan YM, Wang CG, Zhu M, Xing R, Cui JT, et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Mol Cancer 2016;15:79.
50. Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, et al. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther 2017;16:2234-45.
51. He W, Wu J, Shi J, Huo YM, Dai W, et al. IL22RA1/STAT3 signaling promotes stemness and tumorigenicity in pancreatic cancer. Cancer Res 2018;78:3293-305.
52. Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology 2017;6:e1291106.
53. Lin XM, Chen H, Zhan XL. MIR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3. Eur Rev Med Pharmacol Sci 2019;23:6906-13.
54. Peyser ND, Freilino M, Wang L, Zeng Y, Li H, et al. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene 2016;35:1163-9.
55. Peyser ND, Du Y, Li H, Lui V, Xiao X, et al. Loss-of-function PTPRD mutations lead to increased STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. PLoS One 2015;10:e0135750.
56. Gyamfi J, Lee YH, Eom M, Choi J. Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells. Sci Rep 2018;8:8859.
57. Jiang C, Long J, Liu B, Xu M, Wang W, et al. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res 2017;36:99.
58. Saini U, Naidu S, Elnaggar AC, Bid HK, Wallbillich JJ, et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 2017;36:168-81.
59. Escher TE, Lui AJ, Geanes ES, Walter KR, Tawfik O, et al. Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis. Mol Cancer Res 2019;17:1180-94.
60. Chen X, Huang J, Yuchun L. High expression of STAT2 in ovarian cancer and its effect on metastasis of ovarian cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:34-41. (in Chinese)
61. Yang M, Chen H, Zhou L, Chen K, Su F. Expression profile and prognostic values of STAT family members in non-small cell lung cancer. Am J Transl Res 2019;11:4866-80.
62. Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, et al. Positive STAT5 protein and locus amplification status predicts recurrence after radical prostatectomy to assist clinical precision management of prostate cancer. Cancer Epidemiol Biomarkers Prev 2019;28:1642-51.
63. Liao Z, Lutz J, Nevalainen MT. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer. Int J Biochem Cell Biol 2010;42:186-92.
64. Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, et al. IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells. Biochem Biophys Res Commun 2008;369:554-60.
65. von Bubnoff N, Ihorst G, Grishina O, Röthling N, Bertz H, et al. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versushost disease (aGvHD) (NCT02396628). BMC Cancer 2018;18:1132.
66. Lim ST, Jeon YW, Gwak H, Kim SY, Suh YJ. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells. Mol Med Rep 2018;17:5581-8.
67. Kim JW, Gautam J, Kim JE, Kim JA, Kang KW. Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. Oncol Lett 2019;17:3981-9.
68. Taverna JA, Hung CN, DeArmond DT, Chen M, Lin CL, et al. Single-cell proteomic profiling identifies combined AXL and JAK1 inhibition as a novel therapeutic strategy for lung cancer. Cancer Res 2020;80:1551-63.
69. Vallath S, Sage EK, Kolluri KK, Lourenco SN, Teixeira VS, et al. CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity. Sci Rep 2016;6:24006.
70. Yang PW, Huang PM, Yong LS, Chang YH, Wu CW, et al. Circulating interleukin-6 is associated with prognosis and genetic polymorphisms of MIR608 in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2018;25:2449-56.
71. Ojha R, Singh SK, Bhattacharyya S. JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells. Biochim Biophys Acta - Gen Subj 2016;1860:2484-97.
72. Wilson GS, Tian A, Hebbard L, Duan W, George J, et al. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Lett 2013;341:224-30.
73. Morgan EL, Macdonald A. JAK2 inhibition impairs proliferation and sensitises cervical cancer cells to cisplatin-induced cell death. Cancers (Basel) 2019;11:1934.
74. An HJ, Choi EK, Kim JS, Hong SW, Moon JH, et al. INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells. Neoplasma 2014;61:56-62.
75. Radhakrishnan H, Ilm K, Walther W, Shirasawa S, Sasazuki T, et al. MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers. Cancer Lett 2017;403:231-45.
76. Gore J, Craven KE, Wilson JL, Cote GA, Cheng M, et al. TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget 2015;6:7504-21.
77. Perusina Lanfranca M, Zhang Y, Girgis A, Kasselman S, Lazarus J, et al. Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice. Gastroenterology 2020;158:1417-32.e11.
78. Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, et al. Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells. Cancer Res 2017;77:5142-57.
79. Hadjidaniel MD, Muthugounder S, Hung LT, Sheard MA, Shirinbak S, et al. Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget 2017;8:91516-29.
80. Mohrherr J, Haber M, Breitenecker K, Aigner P, Moritsch S, et al. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. Int J Cancer 2019;145:3376-88.
81. Hu Y, Hong Y, Xu Y, Liu P, Guo DH, et al. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in nonsmall-cell lung cancer NSCLC. Apoptosis 2014;19:1627-36.
82. Dolatabadi S, Jonasson E, Lindén M, Fereydouni B, Bäcksten K, et al. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. Int J Cancer 2019;145:435-49.
83. McLean K, Tan L, Bolland DE, Coffman LG, Peterson LF, et al. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. Oncogene 2019;38:1576-84.
84. Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, et al. Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. Oncotarget 2017;8:94040-53.
85. Escobar-Zarate D, Liu YP, Suksanpaisan L, Russell SJ, Peng KW. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther 2013;20:582-9.
86. Cataldi M, Shah NR, Felt SA, Grdzelishvili VZ. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology 2015;485:340-54.
87. Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, et al. Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy. J Natl Cancer Inst 2018;110:1123-32.
88. Patel MR, Dash A, Jacobson BA, Ji Y, Baumann D, et al. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in nonsmall cell lung cancer models. Cancer Gene Ther 2019;26:411-8.
89. Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 2015;33:4039-47.
90. Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs 2018;36:683-95.
91. O’Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, et al. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res Treat 2018;170:547-57.
92. Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, et al. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer 2018;4:10.
93. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
94. Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, et al. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Med 2018;7:5382-93.
95. Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, et al. A placebo-controlled phase II study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer and systemic inflammation. Clin Lung Cancer 2018;19:e567-74.
96. Park JS, Hong MH, Chun YJ, Kim HR, Cho BC. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung Cancer 2019;134:46-51.
97. Yu HA, Perez L, Chang Q, Gao SP, Kris MG, et al. A phase 1/2 trial of Ruxolitinib and Erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to Erlotinib. J Thoracic Oncol 2017;12:102-9.
98. Bauer TM, Rpatel M, Forero-Torres A, George TJ, Assad A, et al. Aphase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors. Onco Targets Ther 2018;11:2399-407.
99. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723-36.
100. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
101. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017;390:457-68.
102. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
103. Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, et al. Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling. Cancer Res 2014;74:6806-19.
104. Seol MA, Kim JH, Oh K, Kim G, Seo MW, et al. Interleukin-7 Contributes to the invasiveness of prostate cancer cells by promoting epithelial-mesenchymal transition. Sci Rep 2019;9:6917.
105. McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 2011;10:2384-93. Page 16 of 18 Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58
106. Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, et al. JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab 2018;27:136-50.e5.
107. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (United States) 2013;15:848-62.
108. Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, et al. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia 2015;17:256-64.
109. Wen W, Wu J, Liu L, Tian Y, Buettner R, et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer 2015;14:100.
110. Plimack ER, LoRusso PM, McCoon P, Tang W, Krebs AD, et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 2013;18:819-20.
111. Su Q, Banks E, Bebernitz G, Bell K, Borenstein CF, et al. Discovery of (2R)-N-[3-[2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino] pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus Kinase 1 (JAK1) inhibitor. J Med Chem 2020;63:4517-27.
112. Sanchez E, Li M, Patil S, Soof CM, Nosrati JD, et al. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. Ann Hematol 2019;98:691-703.
113. Stubbs MC, Burn TC, Sparks R, Maduskuie T, Diamond S, et al. The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies. Clin Cancer Res 2019;25:300-11.
114. Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, et al. A phase Ib/II study of the JAK1 inhibitor, itacitinib, plus nab -paclitaxel and gemcitabine in advanced solid tumors. Oncologist 2019;24:14.
115. Xu L, Feng J, Gao G, Tang H. Momelotinib for the treatment of myelofibrosis. Expert Opin Pharmacother 2019;20:1943-51.
116. Burns CJ, Bourke DG, Andrau L, Bu X, Charman SA, et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorganic Med Chem Lett 2009;19:5887-92.
117. Chan E, Luwor R, Burns C, Kannourakis G, Findlay JK, et al. Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer. Oncotarget 2018;9:16599-618.
118. Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, et al. Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. Front Oncol 2014;4:75.
119. Liu T, Li A, Xu Y, Xin Y. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. Oncol Rep 2019;41:1883-92.
120. Giordano G, Parcesepe P, D’Andrea MR, Coppola L, Di Raimo T, et al. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. J Exp Clin Cancer Res 2019;38:28.
121. Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, et al. Simplify-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol 2017;35:3844-50.
122. Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, et al. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs 2019;37:159-65.
123. Barbie DA, Spira A, Kelly K, Humeniuk R, Kawashima J, et al. Phase 1B study of momelotinib combined with trametinib in metastatic, kirsten rat sarcoma viral oncogene homolog-mutated non-small-cell lung cancer after platinum-based chemotherapy treatment failure. Clin Lung Cancer 2018;19:e853-9.
124. Padda S, Reckamp K, Koczywas M, Neal J, Kawashima J, et al. P2.03-043 a phase 1b study of erlotinib and momelotinib for TKI-Naïve EGFR-mutated metastatic non-small cell lung cancer. J Thorac Oncol 2017;12:S2143-4.
125. Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 2018;4:652-9.
126. Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, et al. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol 2016;9:137.
127. Jensen KV, Cseh O, Aman A, Weiss S, Luchman HA. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One 2017;12:e0189670.
128. Chuang HY, Su Y, Liu HW, Chen CH, Chiu SC, et al. Preclinical evidence of STAT3 inhibitor pacritinib overcoming temozolomide resistance via downregulating miR-21-enriched exosomes from M2 glioblastoma-associated macrophages. J Clin Med 2019;8:959.
129. Jensen KV, Hao X, Aman A, Luchman HA, Weiss S. EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo. Neuro-Oncology Adv 2020;2:vdaa020.
130. Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepatic Oncol 2020;7:HEP18.
131. Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, et al. Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. J Gastrointest Oncol 2017;8:985-9.
132. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26:2435-44.
133. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, et al. WP1066 disrupts janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007;67:11291-9.
134. Tsujita Y, Horiguchi A, Tasaki S, Isono M, Asano T, et al. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of Qureshy et al. J Cancer Metastasis Treat 2020;6:27. I http://dx.doi.org/10.20517/2394-4722.2020.58 Page 17 of 18 bladder cancer cells. Oncol Rep 2017;38:2197-204
135. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9.
136. Huang Y, Zhou X, Liu A, Li S, Wang X, et al. Signal transducer and activator of transcription-3 inhibitor WP1066 affects human tongue squamous cell carcinoma proliferation and apoptosis in vitro and in vivo. Zhonghua Kou Qiang Yi Xue Za Zhi 2014;49:308-13. (in Chinese)
137. Zhou X, Ren Y, Liu A, Han L, Zhang K, et al. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep 2014;31:2173-80.
138. Bai H, Wang C, Qi Y, Xu J, Li N, et al. Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway. BMC Cancer 2019;19:454.
139. Hou J, Lv A, Deng Q, Zhang G, Hu X, et al. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway. Oncol Rep 2019;41:753-64.
140. Zhou Q, Jiang H, Zhang J, Yu W, Zhou Z, et al. Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the stat3 pathway. Cancer Manag Res 2018;10:6339-55.
141. Zhou X, Ren Y, Liu A, Jin R, Jiang Q, et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR21 axis. Sci Rep 2014;4:7461.
142. Cheng CC, Shi LH, Wang XJ, Wang SX, Wan XQ, et al. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int J Oncol 2018;53:339-48.
143. Tang YJ, Sun ZL, Wu WG, Xing J, He YF, et al. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Genet Mol Res 2015;14:2450-60.
144. Palagani V, Bozko P, El Khatib M, Belahmer H, Giese N, et al. Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Carcinogenesis 2013;35:859-66.
145. Fu LX, Lian QW, Pan JD, Xu ZL, Zhou TM, et al. JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling. J Biol Regul Homeost Agents 2017;31:51-8.
146. Faouzi M, Chopin V, Ahidouch A, Ouadid-Ahidouch H. Intermediate Ca2+-sensitive K+ channels are necessary for prolactin-induced proliferation in breast cancer cells. J Membr Biol 2010;234:47-56.
147. Kano Y, Konno M, Kawamoto K, Tamari K, Hayashi K, et al. Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. Oncol Rep 2014;31:1133-8.
148. Xie L, Zeng Y, Dai Z, He W, Ke H, et al. Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. Int J Biol Sci 2018;14:577-85.
149. Zhang L, Xu LJ, Zhu J, Li J, Xue BX, et al. ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgenindependent prostate cancer. Mol Med Rep 2018;17:7045-54.
150. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20.
151. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96.
152. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 2015;1:643-51.
153. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4:e317-24.
154. Li SD, Ma M, Li H, Waluszko A, Sidorenko T, et al. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Med 2017;9:89.
155. Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, et al. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in nonsmall cell lung carcinoma cells with mutated EGF receptor. Oncotarget 2015;6:14329-43.
156. Chen D, Zhang F, Wang J, He H, Duan S, et al. Biodegradable nanoparticles mediated Co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the treatment of ELTN-resistant non-small cell lung cancer (NSCLC) via suppression of the JAK2/STAT3 signaling pathway. Front Pharmacol 2018;9:1214.
157. Gorshkov K, Sima N, Sun W, Lu B, Huang W, et al. Quantitative chemotherapeutic profiling of gynecologic cancer cell lines using approved drugs and bioactive compounds. Transl Oncol 2019;12:441-52.
158. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest 2014;124:553-63.
159. Lin C, Cao W, Ren Z, Tang Y, Zhang C, et al. GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC. Oncoimmunology 2017;6:e1353860.
160. Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 2019;322:315-25.
161. Tarrant JM, Galien R, Li W, Goyal L, Pan Y, et al. Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials. Rheumatol Ther 2020;7:173-90.
162. Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, et al. Preclinical characterization of GLPG0634, a selective Page 18 of 18 Qureshy et al. J Cancer Metastasis Treat 2020;6:27. I http://dx.doi.org/10.20517/2394-4722.2020.58 inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191:3568-77.
163. Chuang CH, Greenside PG, Rogers ZN, Brady JJ, Yang D, et al. Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis. Nat Med 2017;23:291-300.
164. Huang Z, Zhou W, Li Y, Cao M, Wang T, et al. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling. Theranostics 2018;8:4995-5011.
165. Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663-71.
166. Pinto N, Prokopec SD, Vizeacoumar F, Searle K, Lowerison M, et al. Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models. PLoS One 2018;13:e0207152.
167. Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis 2016;75:1057-64.
168. Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-tosevere rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol 2017;69:709-19.
169. Ruan Z, Yang X, Cheng W. OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells. Cancer Manag Res 2019;11:389-99.
170. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;17:78.
171. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 1992;6:3275-82.
172. Ioannidis S, Lamb ML, Wang T, Almeida L, Block MH, et al. Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl) ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway. J Med Chem 2011;54:262-76.
173. Cao JJ, Hood J, Lohse D, Mak CC, McPherson A, et al. WO2007053452A1 - Bi-aryl meta-pyrimidine inhibitors of kinases. Accessed from: https://patents.google.com/patent/WO2007053452A1/el. [Accessed on 12 Aug 2020].
174. Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem 2014;57:9323-42.
175. Huang T, Xue CB, Wang A, Kong L, Ye HF, et al. WO2011112662A1 Piperidin-4-yl azetidine derivatives as jak1 inhibitors. Accessed from: https://patents.google.com/patent/WO2011112662A1/en. [Accessed on 12 Aug 2020].
176. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorganic Med Chem Lett 2002;12:1219-23.
177. Gingrich DE, Hudkins RL. Synthesis and kinase inhibitory activity of 3ʹ-(S)-epi-K-252a. Bioorganic Med Chem Lett 2002;12:2829-31.
178. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-40.
179. William AD, Lee ACH, Blanchard S, Poulsen A, Teo EL, et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19- dioxa-5,7, 26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 2011;54:4638-58.
180. Hamaguchi H, Amano Y, Moritomo A, Shirakami S, Nakajima Y, et al. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorganic Med Chem 2018;26:4971-83.
181. Fridman J, Nussenzveig R, Liu P, Rodgers J, Burn T, et al. Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders. Blood 2007;110:3538.
182. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, et al. Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
